Replies to post #250244 on Biotech Values

[DewDiligence]

ALVR reverse-merges_with Kalaris Therapeutics, a retinal-disease company:

https://www.globenewswire.com/news-release/2024/11/08/2977479/0/en/AlloVir-and-Kalaris-Therapeutics-Announce-Agreement-for-Transformational-Merger-to-Create-Company-Focused-on-Diseases-of-the-Retina.html

Upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company…

After closing, the combined company is expected to operate under the name Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “KLRS.”

… Kalaris is a clinical-stage biopharmaceutical company…dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs, such as neovascular Advanced Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).

A reverse-merger for ALVR was almost inevitable (#msg-173566070).